Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating CD19-CAR T cells (Zola-cel/BMS-986353) versus standard of care in active systemic sclerosis. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Zola-cel (BMS-986353) (BMS-986353)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Systemic Sclerosis | Phase 3 | Status: NOT_YET_RECRUITING